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Introduction {#sec1}
============

Bone marrow-derived mesenchymal stromal cell (BM-MSC)-derived osteoblasts and chondrocytes are responsible for bone and cartilage modeling/remodeling, respectively ([@bib14], [@bib55]). Osteoblasts are defined by lineage-specific transcription factors RUNX2 and OSTERIX, whereas chondrocytes are defined by SOX9 ([@bib20], [@bib31]). In addition, BM-MSCs are capable of differentiating into adipocytes, which are defined by C/EBPα and PPARγ. Under certain conditions, e.g., aging, the lineage differentiation potentials of BM-MSCs are altered. Aged BM-MSCs tend to differentiate into adipocytes at the cost of osteoblasts, which contributes to the pathogenesis of senile osteoporosis and yellowing of the bone marrow ([@bib1], [@bib44]). Reversal of the biased differentiation of aged BM-MSCs is a strategy employed for the prevention/treatment of osteoporosis ([@bib2], [@bib21], [@bib27], [@bib60]). However, how BM-MSC lineage commitment is regulated remains less well understood.

Osteoblast-mediated bone formation is balanced by osteoclast-mediated bone resorption. Osteoclasts are derived from hematopoietic stem cell-derived monocytes, which are defined by transcription factors including PU.1, NF-κB, and NFATc1 ([@bib7]). Under normal conditions, bone formation and resorption are coordinated via complex coupling mechanisms. Some of the osteogenic regulators, e.g., transforming growth factor β1 (TGFβ1), bone morphogenetic proteins (BMPs), and insulin growth factor-1 (IGF-1), are synthesized by osteoclasts or released from bone matrix during resorption ([@bib5], [@bib8], [@bib12], [@bib15], [@bib41], [@bib48]), whereas the master regulators of osteoclast differentiation, macrophage colony stimulating factor (M-CSF), receptor activator of nuclear factor-kappaB ligand (RANKL), and osteoprotegerin (OPG), are believed to be produced by osteoblasts, especially osteocytes ([@bib7], [@bib20], [@bib22], [@bib26], [@bib28]). Disruption of bone formation-resorption coupling underlies the etiology of osteoporosis ([@bib16], [@bib35]).

p38 mitogen-activated protein kinases (MAPKs) are activated by stress, cytokines, and growth factors, some of which are involved in bone development and remodeling, e.g., TGFβ1 and BMPs ([@bib6], [@bib13], [@bib46], [@bib56]). p38 MAPKs phosphorylate a number of transcription factors such as C/EBPα, MEF2, RUNX2, SOX9, and p53 to regulate the expression of many target genes and subsequently cell proliferation, differentiation, and apoptosis ([@bib11], [@bib50]). Ablation of *p38β* or *p38α* in osteoprogenitors or osteoblasts revealed that p38 MAPKs play positive roles in osteoblast maturation, via phosphorylating RUNX2/OSX, without affecting osteoclastogenesis or bone resorption via the coupling mechanisms ([@bib10], [@bib11], [@bib45], [@bib49]). Ablation of *p38α* or constitutive activation of p38 MAPKs in differentiated chondrocytes inhibits their differentiation ([@bib19], [@bib39], [@bib47], [@bib61]). Yet it is still unknown whether p38α plays a role in the stem cells for osteoblasts and chondrocytes, including their self-renewal and cell fate determination. Unlike the differentiated cells, the multipotent BM-MSCs in general do not express lineage-specific transcription factors such as RUNX2 or SOX9, the phosphorylation targets of p38 MAPKs ([@bib11], [@bib50]). Thus, p38 MAPK may employ other mechanisms to decide the fates of BM-MSCs.

Here we ablated *p38α*, the essential *p38* isoform, in BM-MSCs using *Prx1-Cre* and *Dermo1-Cre* mouse lines, respectively, and found that while both *Prx1-Cre; p38α*^*f/f*^ mice and *Dermo1-Cre; p38α*^*f/f*^ mice developed osteoporosis, *Prx1-Cre; p38α*^*f/f*^ mice also showed alterations in growth plate and bone marrow fat. Further studies revealed that p38α plays a role in self-renewal and lineage determination of *Prx1+* BM-MSCs. Moreover, *Prx1-Cre; p38α*^*f/f*^ mice, but not *Dermo1-Cre; p38α*^*f/f*^ mice, showed increased osteoclastogenesis and bone resorption. p38α was found to control OPG production in *Prx1+* BM-MSCs under normal conditions or in response to estrogen. *Prx1-Cre; p38α*^*f/f*^ mice were resistant to ovariectomy-induced bone loss. This study thus reveals that p38α expressed in *Prx1+* cells regulates BM-MSC cell fate decision in a cell-autonomous manner and osteoclastogenesis via controlling production of OPG.

Results {#sec2}
=======

Ablation of *p38α* in *Prx1+* BM-MSCs Leads to Osteoporosis and Cartilage Anomaly {#sec2.1}
---------------------------------------------------------------------------------

To study the functions of p38α in BM-MSCs, we ablated *p38α* with a *Prx1-Cre* mouse line, which has been used to delete genes of interest in BM-MSCs ([@bib9], [@bib30]). Although inconsistent results have been reported regarding the in vivo multipotency of *Prx1+* BM-MSCs, our lineage-tracing experiments using *Prx1-Cre; Rosa-tdTomato* and *Rosa-LacZ* mice confirmed that *Prx1* could label osteoblasts, chondrocytes, and bone marrow adipocytes in vivo ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Immuno-staining of *Prx1-Cre; p38α*^*f/f*^ mouse tissues revealed a great reduction of active p38 MAPKs in osteoblasts and chondrocyte of the bones, but not in skeletal muscle or heart ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The mutant mice were born at the expected Mendelian frequency with normal body weight, yet older mice showed a modest shortening of the hind limbs ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Histological analysis revealed that *p38α* deletion in *Prx1+* BM-MSCs resulted in a decrease in trabecular bone volume and mineralization ([Figure 1](#fig1){ref-type="fig"}A). Histomorphometry analysis and micro-computed tomography (CT) analysis also revealed a decrease in trabecular volume and number, and an increase in trabecular separation ([Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}B). The growth plates were thinner in *Prx1-Cre; p38α*^*f/f*^ mice than in control mice ([Figures 1](#fig1){ref-type="fig"}A and 1C), with a decrease in the number of hypertrophic chondrocytes ([Figure 1](#fig1){ref-type="fig"}C). This may contribute to the short limb phenotype of the mutant mice. In addition, the mutant mice showed an increase in bone marrow fat ([Figures 1](#fig1){ref-type="fig"}D and 1E). These results show that ablation of *p38α* in *Prx1+* BM-MSC and its progenies affects bone mass, cartilage and growth plate, and bone marrow fat, validating the multipotency of *Prx1+* BM-MSCs.

Ablation of *p38α* in *Dermo1+* BM-MSCs Leads to Osteoporosis but Not Cartilage Anomaly {#sec2.2}
---------------------------------------------------------------------------------------

In addition to *Prx1*, *Dermo1* has been implicated as a BM-MSC (or mesenchymal progenitor) marker downstream of *Prx1*, and the *Dermo1-Cre* mouse has been used to generate BM-MSC-specific gene knockout mouse lines as well ([@bib43], [@bib52]). Previous studies showed that bone marrow contains similar numbers of *Prx1+* cells and *Dermo1+* cells ([@bib9], [@bib30], [@bib58]). We then ablated *p38α* using a *Dermo1-Cre* knockin mouse line ([@bib30]). Surprisingly, *Dermo1-Cre; p38α*^*f/f*^ mice did not show a significant defect in growth plate or bone marrow fat ([Figure S1](#mmc1){ref-type="supplementary-material"}E and data not shown), although they showed an osteoporotic phenotype ([Table S1](#mmc1){ref-type="supplementary-material"}). These results suggest that *Dermo1+* BM-MSCs may have limited chondrogenesis potential, thus representing a less primitive BM-MSC population than *Prx1+* BM-MSCs.

p38α Controls Proliferation and Multi-Lineage Differentiation of *Prx1+* BM-MSCs {#sec2.3}
--------------------------------------------------------------------------------

We found that bone formation rates, bone mineralization rates, and the numbers of osteoblasts were all decreased in *Prx1-Cre; p38α*^*f/f*^ mice ([Table 1](#tbl1){ref-type="table"}). However, *p38α* deficiency led to an increase in the number of bone marrow alkaline phosphatase (ALP)-positive colony-forming units ([Figure 2](#fig2){ref-type="fig"}A), an indication of the number of BM-MSCs. This was likely caused by enhanced BM-MSC proliferation, as ablation of *p38α* led to an increase in proliferation rate and KI67-positive cells in BM-MSC cultures ([Figures 2](#fig2){ref-type="fig"}B and 2C, and [S2](#mmc1){ref-type="supplementary-material"}A), which was associated with a decrease in the levels of p53, p21, and p16 ([Figure 2](#fig2){ref-type="fig"}C), negative regulators of cell proliferation that have been shown to be regulated by p38 MAPKs ([@bib53]). *p38α−/−* bone sections also showed an increase (1.79 ± 0.39 fold, n = 3) in the number of KI67-positive cells, including marrow cells ([Figure 2](#fig2){ref-type="fig"}D). However, *p38α* deficiency did not affect the apoptosis rates of BM-MSCs or on bone sections ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).

We then tested the differentiation potentials of *p38α−/−* BM-MSCs and found that *Prx1+* BM-MSCs deficient for *p38α* showed decreased osteogenic differentiation, manifested by a decrease in ALP staining, mineralization, and expression of osteoblast-specific markers such as *Runx2*, *Osx*, *Fra-1*, *Atf4*, *Col1α*, and osteocalcin ([Figures 2](#fig2){ref-type="fig"}E and 2F, and [S2](#mmc1){ref-type="supplementary-material"}D). The mutant cells also showed decreased chondrocyte differentiation ([Figure 2](#fig2){ref-type="fig"}E), accompanied by a decrease in *Sox9* expression ([Figure 2](#fig2){ref-type="fig"}F). The growth plate phenotype appears to be more severe than that in mice with *p38α* ablated in differentiated chondrocytes ([@bib19]). However, the mutant cells showed enhanced adipocyte differentiation ([Figure 2](#fig2){ref-type="fig"}E), accompanied by an increase in *Pparγ* and *C/ebpα* expression ([Figure 2](#fig2){ref-type="fig"}F). Taken together, these results suggest that *p38α* deficiency alters the multi-lineage differentiation potentials of *Prx1*+ BM-MSCs, consistent with thinning of growth plate ([Figures 1](#fig1){ref-type="fig"}A and 1C), and an increase in bone marrow adipocytes observed in *Prx1-Cre; p38α*^*f/f*^ mice ([Figures 1](#fig1){ref-type="fig"}D and 1E).

p38α Regulates BM-MSC Osteogenic Commitment via TAK1-NF-κB Signaling {#sec2.4}
--------------------------------------------------------------------

Previous studies have shown that p38 MAPKs can promote osteoblast differentiation by phosphorylating RUNX2/OSX. Our study and those of others also showed that p38 MAPKs were required for *Osx* expression ([@bib18], [@bib40], [@bib42], [@bib54]). Yet *Runx2* and *Osx* are expressed in osteoprogenitors and osteoblasts but rarely in multipotent BM-MSCs ([Figure 3](#fig3){ref-type="fig"}A). Instead, we found that *p38α−/−* BM-MSCs showed enhanced activation of the TAK1-NF-κB pathway ([Figure 3](#fig3){ref-type="fig"}B), which has been recently shown to inhibit BM-MSC osteogenic differentiation ([@bib3], [@bib57], [@bib59]). p38 MAPKs have been shown to phosphorylate TAB1/2 to inhibit TAK1 activation in several cell types ([@bib4], [@bib53]). We found that inhibition of TAK1 with 5Z-7-oxozeaenol or inhibition of NF-κB with BAY11-7082, reversed the osteogenic differentiation defects of *p38α−/−* BM-MSCs, manifested by the decrease in ALP staining, mineralization staining, and expression of osteoblast markers ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C), although the effects of the inhibitors on osteogenic differentiation of wild-type (WT) BM-MSCs were rather modest. These findings were confirmed by knockdown of *Tak1* or *Nf-κB (p65)* with siRNA in *p38α−/−* BM-MSCs ([Figures 3](#fig3){ref-type="fig"}C and 3D). These results suggest that p38α can regulate osteogenic differentiation of *Prx1+* BM-MSCs via the TAK1-NF-κB pathway. At the later stages of osteoblastogenesis, p38 MAPK may act on RUNX2 and OSTERIX to further promote osteoblast differentiation.

Ablation of *p38α* in BM-MSC Promotes Osteoclastogenesis In Vivo and In Vitro {#sec2.5}
-----------------------------------------------------------------------------

We noticed that in *Prx1-Cre; p38α*^*f/f*^ mice, the extent of the decrease in bone mass (down to 45.4% of the control) exceeds that of the decrease in bone formation rates (down to 74.3% of the control) ([Table 1](#tbl1){ref-type="table"}), suggesting that bone resorption may contribute to the osteoporotic phenotype as well. Indeed, we found that *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in osteoclast surface, the number of osteoclasts ([Figures 4](#fig4){ref-type="fig"}A and 4B), and the levels of urine deoxypyridinoline (DPD), an in vivo bone resorption marker ([Figure 4](#fig4){ref-type="fig"}C), suggesting that ablation of *p38α* in *Prx1+* BM-MSCs promoted osteoclastogenesis and bone resorption in a non-cell-autonomous way. This activity of p38α appears to be unique to *Prx1+*BM-MSCs as previous studies have reported that ablation of *p38α* or *p38β* in osteoprogenitors or osteoblasts did not affect osteoclastogenesis or bone resorption ([@bib10], [@bib45], [@bib49]). We found that ablation of *p38α* in *Dermo1+* cells did not significantly alter the number of osteoclasts or bone resorption rate ([Figure S1](#mmc1){ref-type="supplementary-material"}F). These results, together with our observation that *Dermo1+* cells have minimal chondrogenic activity, suggest that p38α plays an important role in BM-MSC-osteoclastogenesis coupling, but not in osteoprogenitor/osteoblast communication to osteoclastogenesis.

We also found that in co-culture experiments, BM-MSCs were able to support osteoclastogenesis and more importantly, *p38α−/−* BM-MSCs showed a heightened ability in promoting osteoclastogenesis ([Figure 4](#fig4){ref-type="fig"}D). Similarly, the *p38α−/−* BM-MSC culture medium was more capable of promoting osteoclast differentiation than the WT BM-MSC culture medium ([Figure 4](#fig4){ref-type="fig"}E). These results suggest that *p38α* deficiency might affect the synthesis of RANKL, M-CSF, OPG, or other molecules that are involved in regulation of osteoclastogenesis. The finding that ablation of *p38α* in BM-MSCs but not in osteoblasts affects osteoclastogenesis may be explained by differential expression of RANKL, OPG, or M-CSF in BM-MSCs and osteoblasts. Yet qPCR assays revealed that these two cell types expressed similar levels of *Rankl*, *Opg*, and *M-csf* at the mRNA levels ([Figure S4](#mmc1){ref-type="supplementary-material"}).

p38α Regulates the Expression of *Opg* via CREB in *Prx1+* BM-MSCs {#sec2.6}
------------------------------------------------------------------

We found that *p38α* deficiency led to a 4-fold decrease in the mRNA levels of *Opg* ([Figure 5](#fig5){ref-type="fig"}A), and a modest increase in mRNA levels of *M-csf* and *Rankl* ([Figure 5](#fig5){ref-type="fig"}A). A decrease in *Opg* mRNA levels and a modest increase in *Rankl* and *M-csf* levels were also observed in the bone extracts of *Prx1-Cre; p38α*^*f/f*^ mice ([Figure 5](#fig5){ref-type="fig"}B). In co-culture experiments, supplementing the *p38α−/−* BM-MSC-monocytes co-culture with OPG could inhibit osteoclast differentiation ([Figure 5](#fig5){ref-type="fig"}C). These results suggest that *p38α−/−* BM-MSC may promote osteoclastogenesis by down-regulating OPG.

It is likely that p38α controls *Opg* transcription via its downstream transcription factors. Screening of these transcription factors with siRNA revealed that *Creb* may be involved (data not shown). We found that *p38α* deficiency led to a decrease in CREB phosphorylation on Ser133 and moreover, knockdown of *Creb* with siRNA significantly decreased the mRNA levels of *Opg* in normal BM-MSCs ([Figures 5](#fig5){ref-type="fig"}D and 5E), suggesting that CREB is required for expression of OPG in BM-MSCs. Chromatin-immunoprecipitation (ChIP) assays revealed that two CREB binding sites exist in the promoter of *Opg* gene ([Figure 5](#fig5){ref-type="fig"}F). Taken together, our results showed that *Opg* transcription in BM-MSCs is regulated by the p38α-CREB axis and that *Opg* is a target gene of CREB.

*Prx1-Cre; p38α*^*f/f*^ Mice Are Resistant to Estrogen Deficiency-Induced Bone Loss {#sec2.7}
-----------------------------------------------------------------------------------

The above studies revealed that the p38α-CREB-OPG axis in BM-MSCs regulates osteoclastogenesis. One of the pathological conditions that involves osteoblast-osteoclast interaction is estrogen deficiency-induced osteoporosis, which affects more than 50% of women over 50 years of age ([@bib33], [@bib44]). We found that estradiol activated p38 MAPKs in a time- and dose-dependent manner in BM-MSCs ([Figures 6](#fig6){ref-type="fig"}A and 6B), and ovariectomy led to a decrease in p38 MAPKs activation on bone sections, in particular the osteoblast-like cells aligning the trabecular bone surface ([Figure 6](#fig6){ref-type="fig"}C), suggesting that p38α MAPK is a nongenomic signaling molecule of estrogen. Moreover, we found that *p38α* deficiency down-regulated the mRNA and protein levels of estrogen receptor α (ERα) but not ERβ in BM-MSCs and osteoblasts ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), suggesting that p38α is required for optimal expression of ERα in these cells.

Furthermore, estradiol promoted *Opg* expression in WT BM-MSCs but not in *p38α−/−* BM-MSCs, suggesting a necessary role for p38α in estrogen-induced *Opg* expression ([Figure 6](#fig6){ref-type="fig"}D). Moreover, *p38α−/−* osteoblasts were not responsive to estradiol-induced *Opg* expression ([Figure S5](#mmc1){ref-type="supplementary-material"}C). In addition to inhibiting p38 MAPK activation, ovariectomy also down-regulated *Opg* expression in the bone of WT mice. The basal levels of *Opg* in the bones of *Prx1-Cre; p38α*^*f/f*^ mice were low, which could not be further down-regulated by ovariectomy ([Figure 6](#fig6){ref-type="fig"}E). These results suggest that estrogen may induce OPG expression via p38α in BM-MSCs and osteoblasts to suppress osteoclastogenesis. If this p38α-controlled OPG production plays a role in the bone-sparing effects of estrogen, ovariectomy would not further affect osteoclastogenesis or bone resorption in *Prx1-Cre; p38*^*f/f*^ mice due to low levels of OPG. We ovariectomized *Prx1-Cre; p38α*^*f/f*^ and control mice and waited for 4 weeks before analyzing the bone parameters, and found that ovariectomy led to a decrease in bone mass in normal mice, which is accompanied by an increase in the number of osteoclasts and bone resorption rate ([Table 1](#tbl1){ref-type="table"}; [Figures 6](#fig6){ref-type="fig"}F and 6G), yet ovariectomy did not further reduce the bone mass in *Prx1+* BM-MSC-specific *p38α* knockout mice, nor did it further increase the number of osteoclasts or bone resorption rate ([Table 1](#tbl1){ref-type="table"}; [Figures 6](#fig6){ref-type="fig"}F and 6G). Note that ovariectomy showed no significant effect on bone formation in WT or *Prx1-Cre; p38α*^*f/f*^ mice, and estradiol did not show any significant effects on the differentiation of BM-MSCs and osteoblasts ([Table 1](#tbl1){ref-type="table"} and data not shown). These results suggest that estrogen deficiency regulates in vivo osteoclastogenesis and bone resorption mainly through p38α-mediated expression of OPG in *Prx1+* BM-MSCs.

Discussion {#sec3}
==========

As stem cells of the skeleton, BM-MSC\'s lineage commitment, a crucial step thought to determine the yield of functional osteoblasts, needs to be tightly regulated. Yet how BM-MSC lineage commitment is regulated remains poorly understood. This study revealed that p38α MAPK regulates tri-lineage commitment and proliferation of BM-MSCs. p38α MAPK deficiency compromises osteogenic/chondrogenic differentiation but favors adipogenic differentiation, and results in a decrease in bone mass, a defect in growth plate, and an increase in bone marrow fat. Previous studies have implicated that YAP, C-MAF, and VEGF differentially regulate osteoblast and adipogenic differentiation of BM-MSCs ([@bib17], [@bib29], [@bib38]). It will be interesting to test whether there exist links between p38 MAPKs and YAP, C-MAF, or VEGF in the context of BM-MSC lineage commitment. These proteins may present a class of targets for drug development for osteoporosis prevention/treatment.

Our data suggest that p38α may promote BM-MSC osteogenic commitment by suppressing the NF-κB pathway. Previous studies suggest that p38α and p38β promote osteoblast differentiation via modifying RUNX2 and OSX ([@bib11]). But lineage-specific transcription factors such as RUNX2 and OSX are in general not expressed in multipotent BM-MSCs, and thus p38 MAPKs-mediated phosphorylation of these proteins may not be a major factor in determining the cell fates of BM-MSCs ([@bib3], [@bib59]). Thus, p38α may regulate BM-MSC osteogenic commitment and osteoblast maturation with different mechanisms ([Figure 6](#fig6){ref-type="fig"}H). Moreover, p38α may promote BM-MSC osteogenic commitment by suppressing the competing adipogenic or chondrogenic commitment through down-regulating PPARγ, C/EBPα, and SOX9, transcription factors essential for commitment of these two lineages ([@bib23]).

*p38α* deficiency led to a decrease in the number of osteoblasts on bone sections, which can be caused by defective BM-MSC osteogenic differentiation. Surprisingly, the number of BM-MSCs and the BM-MSC proliferation rate were increased in the absence of p38α. This seeming discrepancy may be explained by the fact that mouse bone marrow may contain MSCs that outnumber the bone multicellular units, where new bone formation is occurring. Although *p38α* ablation leads to overproliferation of BM-MSCs, a large portion of these cells may not be actively involved in bone formation. Thus, the number of BM-MSCs is not directly translated into the number of osteoblasts.

We found that the function of BM-MSC-expressed p38α is not limited to osteoblastogenesis and bone formation. We show that p38α-controlled, CREB-mediated OPG production by BM-MSCs is critical for coupling bone formation and resorption. This is in contrast to the findings that ablation of *p38α* or *p38β* in osteoprogenitors/osteoblasts or *Dermo1+* cells failed to affect osteoclastogenesis or bone resorption ([@bib10], [@bib49]). Thus, only p38α expressed in BM-MSCs but not in osteoblasts is involved in communicating with monocytes/osteoclasts under physiological conditions. One explanation is that in a bone remodeling unit, the newly recruited BM-MSCs may secrete OPG to immediately inhibit further osteoclastogenesis, whereas osteoblast-secreted OPG molecules are embedded in the newly formed bone matrix and are not accessible to monocytes/osteoclasts. Alternatively, osteoblasts may have pathways redundant for p38α-OPG to communicate to osteoclastogenesis under physiological conditions.

The p38-CREB-OPG pathway in BM-MSCs is also under the control of estrogen. We show that p38α MAPK can be activated by estrogen and that p38α is also required for optimal expression of ERα. Activated p38α mediates estrogen-induced OPG expression in BM-MSCs, which helps to maintain the bone mass under physiological conditions. Estrogen deficiency leads to a decrease in p38α MAPK activation and OPG synthesis, leading to an increase in osteoclastogenesis and bone resorption ([Figure 6](#fig6){ref-type="fig"}H). As such, *Prx1+* BM-MSC-specific deletion of *p38α* renders the mice resistant to estrogen deficiency-induced bone loss. Interestingly, a recent study reported that mice with *p38α* ablated in osteoblasts are also resistant to ovariectomy-induced bone loss, likely via RANKL and interleukin 6 (IL6) ([@bib51]). These results confirm the important role for p38α in BM-MSCs and osteoblasts in communicating to osteoclastogenesis under estrogen-deficient conditions, although these two cells may use different mechanisms. While recent studies suggest that estrogen may promote osteoclast apoptosis and thus inhibit bone resorption to preserve the bone ([@bib24], [@bib37]), these findings suggest that the contribution of BM-MSC/osteoblast-osteoclast coupling to the pathogenesis of postmenopausal osteoporosis may be greater than previously thought.

Previous studies have shown that BM-MSCs can be labeled by markers including *Prx1*, *Dermo1*, *leptin receptor*, and *Nestin* ([@bib34], [@bib36]). Our lineage-tracing experiments confirm that *Prx1+* BM-MSCs can differentiate into osteoblasts, chondrocytes, and adipocytes in vivo. Moreover, deletion of *p38α MAPK* in *Prx1+* cells affects bone mass, growth plates, and bone marrow fat, as well as osteoclastogenesis and bone resorption. However, deletion of *p38α* in *Dermo1+* cells, like deletion of *p38α* in osteoblasts, only affects BM-MSC osteogenic differentiation and bone formation. These results suggest that *Prx1* may be a much early marker than *Dermo1* and that *Dermo1+* cells may represent a BM-MSC population with limited chondrogenic activity.

In summary, the present study shows that BM-MSC-expressed p38α may take two routes to maintain bone mass and prevent the development of osteoporosis. In particular, p38α is required for proper BM-MSC osteogenic commitment, via the TAK1-NFκB pathway, to maintain proper bone formation, and for OPG synthesis by BM-MSCs to constrain osteoclastogenesis and bone resorption. Moreover, estrogen appears to go through the p38-OPG pathway to preserve the bone. Cytokines or growth factors that can activate p38 MAPKs, e.g., TGFβ1, BMPs, TNFα, and IL6 ([@bib6], [@bib13], [@bib46], [@bib56]), may regulate bone remodeling via p38α as well.

Experimental Procedures {#sec4}
=======================

Mice and Genotyping {#sec4.1}
-------------------

The *p38α*^*f/f*^ mouse line was generated in Dr. Yibin Wang\'s laboratory at UCLA. The *Dermo1-Cre*, *Prx1-Cre*, *Rosa-LacZ*, and *Rosa-tdTamato* mouse lines were purchased from The Jackson Laboratories. These mice were housed in a pathogen-free facility at the Bio-X Institutes at Shanghai Jiao Tong University and the experimental protocol was approved by the Animal Welfare Committee of the University.

Bone Histomorphometry {#sec4.2}
---------------------

Two-month-old mice were injected twice with calcein at a dose of 0.2 mg/20 g body weight with an interval of 7 days and were sacrificed 1 day after the second injection. Bone histomorphometry analysis was carried out following a protocol that has been previously described ([@bib25], [@bib32]). Briefly, the femurs were removed and fixed in 4% paraformaldehyde (PFA) overnight and then stored in 70% alcohol for future experiments. The bones were dehydrated in 95% ethanol overnight, 100% ethanol for 5 hr, 100% ethanol again overnight, and then transferred into xylene overnight, and vacuumed for 30 min. The bones were then embedded with resin, sliced, and stained with Villanueva-Goldner\'s one-step trichrome method. All bone-specific parameters were measured and expressed in units following the guidelines established by the American Society for Bone and Mineral Research histomorphometry nomenclature committee using OsteoMeasure software (OsteoMetrics).

Deoxypyridinoline Measurement {#sec4.3}
-----------------------------

Deoxypyridinoline in the urine was determined to evaluate the bone resorption rate, following the procedure recommended by the manufacturer MicroVue (Quidel).

Bone Marrow Smear and Colony-Forming Unit Assay {#sec4.4}
-----------------------------------------------

Bone marrow cells were flushed out onto slides using α-MEM (Sigma), followed by oil red O and DAPI staining. Adipocytes and total marrow cells were counted on ten randomly selected fields of each smear. Adipocyte number is expressed as a percentage of the total numbers of bone marrow cells. To determine colony-forming units, bone marrow cells were prepared, with red blood cells lysed, and plated at 5 × 10^6^ per well in six-well plates. Fresh complete α-MEM medium was changed every 3 days. Seven days later, the plates were washed with cold PBS, fixed with 4% PFA for 30 min, and stained for ALP (Sigma).

Assays for BM-MSC Osteogenic, Chondrogenic, and Adipogenic Differentiation {#sec4.5}
--------------------------------------------------------------------------

Bone marrow MSCs were isolated from control and mutant mice, which were expanded in BM-MSC stem cell medium to prevent differentiation. BM-MSCs at passage 2 were plated and transfected with siRNA for *Tak1* or *NF-κB (p65)*, or control siRNA, induced to differentiate into osteoblasts in the presence of osteogenic differentiation medium, which contains ascorbic acid and β-glycerolphosphate. An Alkaline Phosphatase Kit (Sigma) was used to stain for ALP enzymatic activity, following the manufacture\'s protocol. To determine mineralization, 21- or 28-day cell cultures were fixed in 4% PFA for 20 min, and stained with alizarin red. Adipogenesis of BM-MSC was induced with a StemPro Adipogenesis Differentiation Kit (Gibco), which was detected by oil red O staining. Chondrogenesis was induced using a StemPro Chondrogenesis Differentiation Kit (Gibco) and staining with 1% Alcian blue solution.

Co-culture of BM-MSC and Monocyte {#sec4.6}
---------------------------------

Co-culture experiments were carried out following a protocol that has been previously described ([@bib25]). Mouse bone marrow was flushed out with α-MEM medium from the femurs and tibias. The monocyte fraction was isolated by centrifugation on a Ficoll plus lymphocyte separation medium gradient (ICN Biomedicals). For co-cultures, primary BM-MSC were plated at 5 × 10^4^ per well in 24-well plates for 24 hr. Upon confluency, freshly isolated bone marrow monocytes were then plated (5 × 10^5^) on top of the BM-MSCs and cultured for 6--10 more days, with the medium being changed every 3 days. The cells were then fixed and stained for tartrate-resistant acidic phosphatase (TRAP) using the Acid Phosphatase, Leukocyte TRAP Kit (Sigma), following the manufacturer\'s protocol. TRAP-positive multinucleated osteoclasts were counted (≥3 nuclei).

Immunohistochemical Staining and TUNEL Assay {#sec4.7}
--------------------------------------------

Detection of p-p38MAPK was performed on paraffin sections of femur or tibia by immunohistochemistry staining. Tissue sections were processed with an antigen retrieval step before they were incubated with anti-p-p38 antibodies overnight at 4°C. These slides were then washed three times with PBS, incubated with horseradish peroxidase-labeled anti-rabbit antibody for 30 min at 37°C, and developed with diaminobenzidine tetrahydrochloride and hydrogen peroxide in PBS. Cell proliferation and apoptosis were determined by KI67 immunofluorescence staining (Abcam, ab15580) and TUNEL assay (In Situ Cell Death Detection Kit Fluorescein, Roche), respectively.

Western Blot Analysis {#sec4.8}
---------------------

BM-MSC or osteoclasts were lysed with TNEN buffer supplemented with protease inhibitors and phosphatase inhibitors. Protein concentration was determined using a Bio-Rad assay. Twenty micrograms of protein lysates of each sample was subjected to SDS-PAGE analysis and transferred onto nitrocellulose membranes. The proteins were detected with specific antibodies (listed in the [Supplemental Information](#app2){ref-type="sec"}).

ChIP Assays {#sec4.9}
-----------

ChIP assays were carried out following the protocol from the SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling, 9002). Briefly, BM-MSCs or osteoclasts (4 × 10^7^) were treated with 1% formaldehyde for 10 min at room temperature to crosslink proteins to DNA. The chromatin was harvested and fragmented using enzymatic digestion. An aliquot of each sample was set aside as input control, while the remaining portion was subjected to immunoprecipitation with anti-CREB antibodies (Upstate, 05767) overnight at 4°C, with IgG (Beyotime) as control. Immunoprecipitated complex was treated with protease and the DNA was amplified by PCR using primer pairs designed to amplify about 100-bp fragments spanning the 2-kb *Opg* promoter (BM-MSCs).

Data Analysis {#sec4.10}
-------------

For bone histomorphometry analysis, eight mutant and eight control mice were used. For ex vivo studies, at least three pairs of mice were used. In vitro experiments were repeated three times. Results are presented as means ± SEM. Statistical comparisons were performed using unpaired Student\'s two-tailed t test. p \< 0.05 was considered statistically significant (^∗^p \< 0.05, ^∗∗^p \< 0.01 when mutant mice were compared with control mice, siRNA knockdown cells were compared with control cells, or the inhibitor-treated group were compared with control group).
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![Deletion of *p38α* in *Prx1+* BM-MSCs Led to Osteoporosis and Growth Plate Defects\
(A) Representative images of H&E and Von Kossa staining of the femur bones of 10-week-old *Prx1-Cre; p38α*^*f/f*^ and control mice to show trabecular bones (upper panel, scale bar, 200 μm), bone mineralization (middle panel, scale bar, 200 μm), and growth plate (lower panel, scale bar, 50 μm).\
(B) Micro-CT results confirmed that *Prx1-Cre; p38α*^*f/f*^ mice showed a decrease in bone mass. Bottom panel: quantitation data. Data represent means ± SEM of eight independent experiments, ^∗∗^p \< 0.01.\
(C) The growth plates at a higher magnification. Arrows indicate hypertrophic chondrocytes. Scale bar, 50 μm.\
(D) The *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in bone marrow fat. *p38α* deficiency led to an increase in bone marrow adipocytes in 8-month-old mice. Arrows indicate the adipocytes in H&E staining. Scale bar, 50 μm.\
(E) The bone marrow smear assay also revealed an increase in bone marrow fat cells in the mutant mice. Right panel: quantitation data. Scale bar, 20 μm. Data represent means ± SEM of three independent experiments. ^∗^p \< 0.05.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![*p38α* Ablation Enhanced Proliferation of *Prx1+* BM-MSCs and Resulted in Skewed BM-MSC Tri-lineage Differentiation\
(A) *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in the number of ALP-positive colony-forming units. A total of 5 × 10^6^ cells/well was plated onto six-well plates, which were stained for ALP after 7 days in culture. Bottom panel: quantitation data. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(B) *p38α−/−* BM-MSC showed increased proliferation. WT and *Prx1-Cre; p38α*^*f/f*^ BM-MSCs were cultured in BM-MSC culture medium and cells were counted at different time. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(C) Ablation of *p38α* in BM-MSC showed a decrease in p38α, p16, p53, and p21 protein levels compared with control cells. The BM-MSCs were isolated from WT and *Prx1-Cre; p38α*^*f/f*^ mice, cultured in BM-MSC culture medium to log phase, and were then collected. The protein levels of these genes were analyzed by western blot.\
(D) *p38α−/−* bone sections also showed an increase in the number of KI67-positive cells. Scale bar, 100 μm.\
(E) *p38α−/−* BM-MSC showed an alteration in differentiating into the three lineages. WT and *p38α−/−* BM-MSCs were cultured in differentiation medium for osteoblasts, chondrocytes, or adipocytes for different periods of time and then stained for ALP, mineralization, Alcian blue (scale bar, 100 μm), or oil red O (scale bar, 20 μm). Right panel: quantitation data to show the numbers of chondrocytes and adipocytes per well. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(F) *p38α−/−* BM-MSCs showed an alteration in the expression of lineage-specific transcription factors and functional molecules. The cells were cultured as described in [Figure 3](#fig3){ref-type="fig"}E, from which total RNA was isolated. qPCR was used to determine the mRNA levels of these genes. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![p38α Regulated BM-MSC Osteogenic Differentiation via TAK1-NF-κB Signaling\
(A) *p38α−/−* and WT BM-MSCs showed minimal expression of *Runx2* and *Osx*. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(B) *p38α−/−* BM-MSCs showed enhanced TAK1-NF-κB signaling. BM-MSCs were isolated from *p38α*^*f/f*^ mice and cultured in BM-MSC medium, infected with Cre-expressing retrovirus or empty retrovirus, selected against puromycin, and then collected. The activation and protein levels of TAK1, NF-κB, and p38α were determined by western blot analysis.\
(C) Knockdown of *Tak1* or *Nf-κb p65* with siRNA rescued the osteogenic differentiation defect of *p38α−/−* BM-MSCs. WT and *p38α−/−* BM-MSCs were transfected with control, *Tak1*, or *Nf-κb* siRNA for 2 days and then cultured in osteoblast differentiation medium for 4 more days. The cells were stained for ALP (right panel). Left panel: western blot results of knockdown of TAK1 or NF-κB.\
(D) qPCR results showed that knockdown of *Tak1* or *Nf-κb p65* with siRNA rescued the osteogenic differentiation defect of *p38α−/−* BM-MSCs. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Ablation of *p38α* in *Prx1+* BM-MSCs Promoted Osteoclastogenesis and Bone Resorption\
(A) *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in the osteoclast surface per bone surface. Data represent means ± SEM of eight independent experiments, ^∗^p \< 0.05.\
(B) *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in the number of osteoclasts per bone surface. Data represent means ± SEM of eight independent experiments, ^∗^p \< 0.05.\
(C) *Prx1-Cre; p38α*^*f/f*^ mice showed an increase in the levels of urine DPD. Urine levels of DPD were determined with an ELISA kit and were normalized to urine levels of creatine. Data represent means ± SEM of eight independent experiments, ^∗^p \< 0.05.\
(D) Co-culture experiments showed that *p38α−/−* BM-MSCs had increased potential to support osteoclastogenesis. WT and *p38α−/−* BM-MSCs were plated in BM-MSC culture medium and, after 24 hr, bone marrow monocytes isolated from normal mice were added onto the BM-MSC cultures, which were cultured in the absence of RANKL or M-CSF. After 7 days, the plates were stained for TRAP. Right panel: quantitation data to show the number of osteoclasts per view. Scale bar, 100 μm. Data represent means ± SEM of three independent experiments, ^∗^p \< 0.05.\
(E) *p38α−/−* BM-MSC culture medium also showed increased potential to support osteoclastogenesis. Right panel: quantitation data to show the number of osteoclasts per view. Scale bar, 100 μm. Data represent means ± SEM of three independent experiments, ^∗^p \< 0.05.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![p38α Positively Regulated OPG Expression via CREB\
(A) *p38α−/−* BM-MSCs showed a decreased expression of OPG and a modest increase in RANKL and M-CSF compared with WT BM-MSCs. Total RNA was isolated from WT and *p38α−/−* BM-MSCs and was used to determine the mRNA levels of *Opg*, *Rankl*, and *M-csf*. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(B) *Prx1-Cre; p38α*^*f/f*^ mouse bones also showed a decrease in *Opg* mRNA levels and a modest increase in *Rankl* and *M-csf*. The femur bones were frozen and total RNA was isolated. Data represent means ± SEM of six independent experiments, ^∗∗^p \< 0.01.\
(C) Addition of OPG to the *p38α−/−* BM-MSCs co-cultured with normal monocytes impeded the enhanced osteoclast differentiation. The experiments were carried out as described in [Figure 4](#fig4){ref-type="fig"}D, except that OPG (20 ng/ml) was added to the cultures. Scale bar, 100 μm.\
(D) *p38α−/−* BM-MSCs showed a decrease in CREB phosphorylation. WT and *p38α−/−* BM-MSCs were collected and lysed. The levels of CREB and p-CREB were determined by western blot.\
(E) Knockdown of *Creb* led to a down-regulation of *Opg* in normal BM-MSCs. BM-MSCs were transfected with control or siRNA against *Creb*. qPCR was carried out to determine the mRNA levels of *Opg*. Right panel: western blot showing the knockdown of CREB. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(F) ChIP experiments showed that *Opg* promoter has two CREB binding sites at −501 to −601 and −1201 to −1301. Right panel: a diagram showing the binding sites of CREB in the promoter of *Opg* gene. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.](gr5){#fig5}

![The p38-OPG Axis in BM-MSCs Participated in Estrogen Deficiency-Induced Osteoporosis\
(A) Estradiol activated p38 MAPKs in a time-dependent manner in BM-MSCs. Normal BM-MSCs were stimulated with 10 nM of estradiol for different periods of time and the activation of p38 MAPKs was determined by western blot.\
(B) Estradiol activated p38 MAPKs in a dose-dependent manner in BM-MSCs.\
(C) Ovariectomy diminished p38 MAPKs activation on bone sections. WT mice were ovariectomized or sham-operated. The femur bones were decalcified, and immuno-stained for p-p38 MAPKs. The bone from *Prx1-Cre; p38α*^*f/f*^ mice was used as a negative control. The red dashed lines mark the bone surfaces. Scale bar, 100 μm.\
(D) Estradiol induced *Opg* expression in a p38α-dependent manner. WT and *p38α−/−* BM-MSCs were treated with estradiol for 24 hr and the mRNA levels of *Opg* were determined with qPCR. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(E) Ovariectomy down-regulated *Opg* expression in the bone in a p38α-dependent manner. Total RNA was isolated from femur bones and *Opg* levels were determined with qPCR. Data represent means ± SEM of three independent experiments, ^∗∗^p \< 0.01.\
(F) Ovariectomy did not further increase the number of osteoclasts in *Prx1-Cre; p38α*^*f/f*^ mice. Data represent means ± SEM of eight independent experiments, ^∗∗^p \< 0.01.\
(G) Ovariectomy did not further increase the level of urine DPD levels in *Prx1-Cre; p38α*^*f/f*^ mice. Data represent means ± SEM of eight independent experiments, ^∗∗^p \< 0.01.\
(H) A diagram showing how p38α is involved in osteoblastogenesis, osteoclastogenesis, and their coordination during bone remodeling.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

###### 

Histomorphometry Parameters of *Prx1-Cre; p38α*^*f/f*^ and Control Mice, Ovariectomized *Prx1-Cre; p38α*^*f/f*^ and Control Mice

                  *p38α*^*f/f*^     *Prx1-Cre; p38α*^*f/f*^   *p38α*^*f/f*^*OVX*    *Prx1-Cre; p38α*^*f/f*^*OVX*
  --------------- ----------------- ------------------------- --------------------- ------------------------------
  BV/TV (%)       22.914 ± 5.66     10.336 ± 5.79^∗∗^         15.552 ± 2.76^∗∗^     12.017 ± 3.99
  Tb.Ar (%)       19.711 ± 4.90     5.827 ± 2.78^∗∗^          12.241 ± 2.09^∗∗^     8.238 ± 2.36
  Tb.Th (μm)      36.669 ± 2.86     18.766 ± 3.13^∗∗^         26.768 ± 2.88^∗∗^     20.713 ± 4.52
  Tb.Sp (μm)      193.124 ± 30.73   540.127 ± 211.85^∗^       355.784 ± 41.12^∗∗^   448.729 ± 28.23
  Tb.N (no./mm)   5.950 ± 0.76      2.70 ± 1.51^∗∗^           3.646 ± 0.33^∗∗^      2.769 ± 0.41
  MAR (μm/d)      1.749 ± 0.168     1.243 ± 0.097^∗∗^         1.768 ± 0.096         1.240 ± 0.188
  BFR (μm/d)      75.880 ± 3.896    56.437 ± 4.58^∗∗^         71.771 ± 3.88         55.970 ± 6.1
  OB.S/BS (%)     17.016 ± 1.096    11.600 ± 1.68^∗∗^         16.001 ± 1.00         11.933 ± 0.95

Data represent means ± SEM of eight independent experiments, ^∗∗^p \< 0.01, ^∗^p \< 0.05 when the value of mutant or ovariectomized mice was compared with that of control mice.

See also [Table S1](#mmc1){ref-type="supplementary-material"}.
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